SEC Form 4 · accession 0001193125-26-310991
Aktis Oncology, Inc. · AKTS
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Ken Herrmann
Director
Period of report
Jul 20, 2026
Accepted (ET)
Jul 21, 2026 · 8:50 pm EDT
Rule 10b5-1 plan
box not checked
Issuer CIK
0002035832
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common Stock | Jul 20, 2026 | M | 3,506 | $0.08 | A | 3,506 | D | |
| Common Stock | Jul 20, 2026 | M | 1,350 | $1.91 | A | 4,856 | D | |
| Common StockF1 | Jul 20, 2026 | S | 3,506 | $24.5622 | D | 1,350 | D | |
| Common StockF1 | Jul 20, 2026 | S | 1,350 | $24.5622 | D | 0 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Stock Option (Right to Buy)F2 | $0.08 | Jul 20, 2026 | M | 3,506 | D | — | Nov 23, 2030 | Common Stock | 3,506 | 0 | D |
| Stock Option (Right to Buy)F2 | $1.91 | Jul 20, 2026 | M | 1,350 | D | — | Apr 14, 2031 | Common Stock | 1,350 | 18,364 | D |
Explanation of responses
- F1The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $24.50 to $24.66, inclusive. The reporting person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range.
- F2These options have vested in full.